Oncimmune Ltd. is seeking new distribution partners in the US as it expands commercialization of its a one-of-a-kind immunoassay for early-stage lung cancer that can detect circulating antibodies in the blood of patients with lung cancer up to four years before standard imaging tests. Positive interim data from a UK randomized clinical trial is expected to help fuel uptake of the test.
Oncimmune Ltd. is seeking new distribution partners in the US as it expands the commercialization of its blood-based immunoassay for early-stage lung cancer, the only one of its kind in the market.
The EarlyCDT-Lung test works by measuring autoantibodies that are produced by the body in response to proteins produced by lung...
The UK's regulatory agency is the first to join a new international network for oversight of AI in healthcare run by a non-profit organization, HealthAI, the global agency for responsible AI in health.
The Modern Industrial Strategy is the first of this summer’s UK blueprints for supporting life sciences industrial activity and transforming NHS healthcare delivery. The UK market must also benefit from its own innovation activity, says industry.
NHS England will offer at-home cervical cancer self-testing kits to people who are overdue for routine screening by six months. The Department of Health and Social Care identified four HPV collection and testing combinations with highest accuracy.
"The AI Airlock program creates a supervised testing ground where novel technologies and challenge areas can be safely investigated," said James Pound, MHRA interim executive director of innovation and compliance.
NHS England will offer at-home cervical cancer self-testing kits to people who are overdue for routine screening by six months. The Department of Health and Social Care identified four HPV collection and testing combinations with highest accuracy.
"The AI Airlock program creates a supervised testing ground where novel technologies and challenge areas can be safely investigated," said James Pound, MHRA interim executive director of innovation and compliance.
The EU is testing a groundbreaking “all-in-one” process for reviewing combined drug and diagnostic trials via a single application for coordinated assessment.
